Brief: Ocugen Announces First Patient Dosed In Phase 1/2 Clinical Trial of OCU410
13/12/2023 12:48
Dec 13 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
CLINICAL
TRIAL EVALUATING THE SAFETY AND EFFICACY OF OCU410—MODIFIER GENE
THERAPY—FOR GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED
MACULAR DEGENERATION
Source text for Eikon: ID:nGNX3RWD15
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))